Poster

INHALE-1: A 26-week Primary Treatment with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® vs Rapid-Acting Analogue Insulin in Pediatric Subjects with Diabetes

Michael Haller, presented by Jamie Wood